Delving into the Latest Updates on NY-ESO-1 OLP4(Memorial Sloan Kettering Cancer Center) with Synapse

Overview

Basic Info

Drug Type

Shared antigen vaccine, Synthetic peptide vaccine, Therapeutic vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [2]

Active Indication-

Inactive Indication

Fallopian Tube CarcinomaOvarian Epithelial CarcinomaPrimary peritoneal carcinoma+ [1]

Originator Organization

Memorial Sloan Kettering Cancer Center

Active Organization-

Inactive Organization

Ludwig Institute for Cancer Research Ltd.

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

This was a Phase 1, open-label, non-randomized study of the combination of NY-ESO-1 plus ipilimumab in patients with unresectable or metastatic melanoma for whom treatment with ipilimumab was indicated. Patients must have had evidence of NY-ESO-1 or LAGE-1 tumor positivity and radiologically measurable disease by the immune-related Response Criteria (irRC). Primary study objectives were to determine the safety and tolerability of the combination and to evaluate humoral and cellular immune response. Secondary objectives were to evaluate tumor response and immunological changes in the tumor microenvironment.

Start Date24 Jan 2014

Sponsor / Collaborator

Ludwig Institute for Cancer Research Ltd.

NCT00616941

/ CompletedPhase 1IIT

A Phase 1 Study of NY-ESO-1 Overlapping Peptides With or Without Immunoadjuvants Montanide and Poly-ICLC Vaccination of Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer Patients in Second or Third Remission

This was a Phase 1, open-label study of repeated vaccination with NY-ESO-1 overlapping peptides (OLP4) with or without the immunoadjuvants Montanide and polyinosinic-polycytidylic acid - poly-L-lysine carboxymethylcellulose (poly-ICLC) administered every 3 weeks for a total of 5 vaccinations in subjects with epithelial ovarian, fallopian tube, or primary peritoneal cancer in second or third clinical remission. Study objectives included determination of the safety and immunogenicity following vaccination.

Start Date01 Mar 2008

Sponsor / Collaborator

Ludwig Institute for Cancer Research Ltd.

[+1]

NCT00112957

/ CompletedPhase 2IIT

Phase II Study of Recombinant Vaccinia-NY-ESO-1 (rV-NY-ESO-1) and Recombinant Fowlpox-NY-ESO-1 (rF-NY-ESO-1) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen

This was a Phase 2, single-center, open-label study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) injections in patients who had a complete response to standard therapy for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma and whose tumors expressed NY-ESO-1 or LAGE-1 antigen. Study objectives were to evaluate maintenance of remission at 12 months, time to failure of vaccine therapy, cellular and humoral immunity and any correlation with time to failure, and safety.

Start Date01 Dec 2004

Sponsor / Collaborator

Ludwig Institute for Cancer Research Ltd.

[+1]

100 Clinical Results associated with NY-ESO-1 OLP4(Memorial Sloan Kettering Cancer Center)

Login to view more data

100 Translational Medicine associated with NY-ESO-1 OLP4(Memorial Sloan Kettering Cancer Center)

Login to view more data

100 Patents (Medical) associated with NY-ESO-1 OLP4(Memorial Sloan Kettering Cancer Center)

Login to view more data

100 Deals associated with NY-ESO-1 OLP4(Memorial Sloan Kettering Cancer Center)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Unresectable Melanoma	Phase 1	United States	Ludwig Institute for Cancer Research Ltd.	24 Jan 2014
Unresectable Melanoma	Phase 1	Australia	Ludwig Institute for Cancer Research Ltd.	24 Jan 2014
Fallopian Tube Carcinoma	Phase 1	United States	Ludwig Institute for Cancer Research Ltd.	01 Mar 2008
Ovarian Epithelial Carcinoma	Phase 1	United States	Ludwig Institute for Cancer Research Ltd.	01 Mar 2008
Primary peritoneal carcinoma	Phase 1	United States	Ludwig Institute for Cancer Research Ltd.	01 Mar 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01810016 (P366, SITC2019)	Phase 1	Melanoma NY-ESO-1+	8	IPI + NY-ESO-1 protein + pICLC + Montanide	sopracfyal(cokubnungr) = dciyaradsd jdklysfpsr (moqzqmpvph ) View more	Positive	01 Nov 2019
				IPI + NY-ESO-1 OLP4 + pICLC + Montanide	sopracfyal(cokubnungr) = exuydyndqi jdklysfpsr (moqzqmpvph ) View more
NCT01810016 (P366, CTgov)	Phase 1	Unresectable Melanoma	8	Arm A (Arm A (Ipi, NY-ESO-1 Protein))	jpbqkbwude(wdkymerwmh) = rrylupgrbi umkkqleheg (gqvbehmnqi, vgwcmhkyvm - abwhpasxie) View more	-	30 Nov 2018
				Ipi+NY-ESO-1 OLP4 (Arm B (Ipi, NY-ESO-1 OLP4))	jpbqkbwude(wdkymerwmh) = tuzguogdet umkkqleheg (gqvbehmnqi, veobucezbr - ldjznqahrw) View more
NCT00616941 (CTgov)	Phase 1	Primary peritoneal carcinoma \| Ovarian Epithelial Carcinoma \| Fallopian Tube Carcinoma	28	NY-ESO-1 OLP4 (Cohort 1)	qhjdlhgnqo(ioacaydwks) = xddwpvdfdt rolngqcfvn (nxxhmczirn, kfauxtbrtc - hyexhacmcm) View more	-	27 Jul 2018
				NY-ESO-1 OLP4 + Montanide (Cohort 2)	qhjdlhgnqo(ioacaydwks) = zcmamzcson rolngqcfvn (nxxhmczirn, tazwfbchaj - xusqqfhwrt) View more
NCT00112957 (CTgov)	Phase 2	Primary peritoneal carcinoma \| Ovarian Cancer \| Fallopian Tube Carcinoma	23	rV-NY-ESO-1 vaccine	ohixrxtbgr(jpfxgjznyf) = acsgdoiyul gxhuxjkalr (ufgbtwlpwn, etfvtpgtlk - fhzvzlfdde) View more	-	19 Mar 2018